S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NYSEAMERICAN:CPHI - China Pharma Stock Price, Forecast & News

$0.67
+0.05 (+8.05 %)
(As of 03/30/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.62
Now: $0.67▼
$0.68
50-Day Range N/A
52-Week Range
$0.21
Now: $0.67▼
$1.40
Volume1.09 million shs
Average Volume4.12 million shs
Market Capitalization$29.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
Read More

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CPHI
Previous SymbolNYSEMKT:CPHI
CUSIPN/A
CIKN/A
Webhttp://www.chinapharmaholdings.com/
Phone8689866811730

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees240
Outstanding Shares43,580,000
Market Cap$29.25 million
Next Earnings Date3/31/2020 (Confirmed)
OptionableNot Optionable

Receive CPHI News and Ratings via Email

Sign-up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter.

AMEX:CPHI Rates by TradingView

China Pharma (NYSEAMERICAN:CPHI) Frequently Asked Questions

When is China Pharma's next earnings date?

China Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 31st 2020. View our earnings forecast for China Pharma.

How were China Pharma's earnings last quarter?

China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) posted its quarterly earnings data on Wednesday, August, 15th. The company reported ($0.02) EPS for the quarter. The firm earned $3.17 million during the quarter. View China Pharma's earnings history.

Has China Pharma been receiving favorable news coverage?

Media headlines about CPHI stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. China Pharma earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View the latest news aboutChina Pharma.

Are investors shorting China Pharma?

China Pharma saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 624,500 shares, an increase of 174.0% from the February 27th total of 227,900 shares. Based on an average trading volume of 3,580,000 shares, the short-interest ratio is currently 0.2 days. Currently, 2.9% of the shares of the company are sold short. View China Pharma's Current Options Chain.

Who are some of China Pharma's key competitors?

What other stocks do shareholders of China Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Pharma investors own include NovaBay Pharmaceuticals (NBY), Inovio Pharmaceuticals (INO), Novavax (NVAX), Agile Therapeutics (AGRX), Jaguar Health (JAGX), Micron Technology (MU), Ibio (IBIO), Biocept (BIOC), AbbVie (ABBV) and Canopy Growth (CGC).

Who are China Pharma's key executives?

China Pharma's management team includes the following people:
  • Ms. Zhilin Li, Pres, CEO, Chairman & Interim CFO (Age 66)

What is China Pharma's stock symbol?

China Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CPHI."

Who are China Pharma's major shareholders?

China Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.05%).

Which institutional investors are buying China Pharma stock?

CPHI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of China Pharma?

Shares of CPHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is China Pharma's stock price today?

One share of CPHI stock can currently be purchased for approximately $0.67.

How big of a company is China Pharma?

China Pharma has a market capitalization of $29.25 million. China Pharma employs 240 workers across the globe. View additional information about China Pharma.

What is China Pharma's official website?

The official website for China Pharma is http://www.chinapharmaholdings.com/.

How can I contact China Pharma?

China Pharma's mailing address is 2Nd Floor, No. 17, Jinpan Road, Haikou, HAIKOU, HAN 570216, China. The company can be reached via phone at 8689866811730.


MarketBeat Community Rating for China Pharma (NYSEAMERICAN CPHI)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about China Pharma and other stocks. Vote "Outperform" if you believe CPHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Earnings Reports
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel